10.8%
Revenue Growth
RMD's revenue increased by 10.8% year-over-year, driven by strong sales performance across key markets.
Source: Source: 10-Q Income Statement, p.1
AI Takeaway
RMD reported strong financial performance in Q3 FY2026, with significant revenue growth and improved margins, driven by increased sales and effective cost management.
Revenue
$1.43B
++10.81% YoY
EPS (Basic)
$2.74
++10.04% YoY
Gross Margin
62.2%
++2.91% YoY
Operating Income
$499.81M
++17.25% YoY
Filed · Analysis updated · Source: SEC EDGAR 10-Q filing
RMD's revenue increased by 10.8% year-over-year, driven by strong sales performance across key markets.
Source: Source: 10-Q Income Statement, p.1
Gross margin improved to 62.2%, reflecting better cost management and higher operational efficiency.
Source: Source: 10-Q Income Statement, p.1
R&D expenses rose by 12.3%, indicating a focus on innovation and product development.
Source: Source: 10-Q Income Statement, p.1
Potential disruptions in the supply chain could impact production and delivery schedules, affecting revenue and profitability.
Source: Source: Industry Analysis
Unlock 2 more detailed risk analysis
Upgrade to unlockReported EPS of $2.86 versus the $2.82 analyst consensus — a +1.3% beat for Q3 FY2026.
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $1.43B | $1.29B | +10.81% |
Cost of Revenue | $540.43M | $525.33M | +2.87% |
Gross Profit | $890.98M | $766.41M | +16.25% |
Operating Income | $499.81M | $426.27M | +17.25% |
Net Income | $398.73M | $365.04M | +9.23% |
EPS (Basic) | $2.74 | $2.49 | +10.04% |
EPS (Diluted) | $2.74 | $2.48 | +10.48% |
R&D Expense | $94.27M | $83.94M | +12.30% |
SG&A Expense | $285.65M | $245.3M | +16.45% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $8.78B | $7.57B | +16.09% |
Current Assets | $4.06B | $3.21B | +26.67% |
Total Liabilities | $2.29B | $2.02B | +13.45% |
Current Liabilities | $1.35B | $940.52M | +43.67% |
Stockholders' Equity | $6.49B | $5.55B | +17.05% |
Cash & Equivalents | $1.66B | $932.71M | +78.03% |
Long-Term Debt | $404.17M | $663.13M | -39.05% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash FlowYTD | $1.35B | $1.21B | +11.41% |
Investing Cash FlowYTD | $-161.55M | $-66.33M | -143.54% |
Financing Cash FlowYTD | $-743.87M | $-442.37M | -68.16% |
Dividends PaidYTD | $262.57M | $233.29M | +12.55% |
Share BuybacksYTD | $500.04M | $200.02M | +150.00% |
D&A | $58.98M | $43.67M | +35.05% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Gross Margin | 62.2% | 59.3% | +2.91% |
Operating Margin | 34.9% | 33.0% | +1.92% |
Net Margin | 27.9% | — | — |
ROE | 6.1% | — | — |
ROA | 4.5% | — | — |
Current Ratio | $3.008 | — | — |
Debt to Equity | $0.353 | — | — |
Other companies in Health Care Equipment
The filing does not provide specific earnings estimates, but RMD showed strong performance with a 10.8% revenue increase and a 10.0% rise in EPS.
Key takeaways include a 10.8% revenue growth, improved gross margin to 62.2%, and a significant increase in R&D investment by 12.3%.
RMD's revenue grew by 10.8% year-over-year to $1.43B, driven by strong sales across key markets.
RMD shows strong financial health with a current ratio of 3.01, indicating good liquidity, and a decrease in long-term debt by 39.1%.
Key risks include supply chain disruptions, currency fluctuations, and regulatory changes, which could impact operations and profitability.